2 Patients Randomized. $3,000 Per Randomized Patient.
An AstraZeneca-sponsored COPD study site completed enrollment for two targeted slots through a focused campaign, backed by a randomization commitment.
Book a Free Consultation2
Patients Randomized
$6,000
Campaign Investment
$3,000
Cost Per Randomized Patient
Sponsor
AstraZeneca, in collaboration with Amgen
Drug
Tezepelumab (TEZSPIRE)
Phase
3
Condition
COPD, moderate to very severe
Key eligibility
Age 40–80, COPD diagnosis of 12+ months, documented inhaled therapy for 3+ months, 2+ moderate or 1+ severe exacerbations in the prior 12 months, current or former smoker, body weight 40kg+
Site profile
Single study site
Registration
NCT06883305 on ClinicalTrials.gov
Two Slots. Tight Timeline. No Margin for Vendor Risk.
Some enrollment challenges are not about volume. They are about precision. This AstraZeneca-sponsored COPD study site needed to fill two randomization slots within a fixed protocol window. A missed slot could not be recovered. The timeline was defined.
Traditional recruitment vendors carried the same structural risk that affects most sites working with externally sourced patient recruitment: fees payable regardless of whether patients are randomized. For a small, targeted enrollment need with no room for error, that financial structure was not acceptable. The site needed a partner accountable for outcomes, not activity.
At $6,000 in campaign investment, the question was whether a recruitment partner could commit to delivering within it.
Targeted Campaign. Pre-Screened Referrals. Defined Outcome.
Feasibility confirmed two randomizable COPD patients could be reached within the site's geographic and demographic patient pool given the protocol's inclusion criteria. Clinical Enroll developed an IRB-ready campaign with pre-screening built into the referral process. The randomization commitment was formalized in contract before campaign launch.
Both Slots Filled. Protocol Window Met.
The campaign delivered 2 randomized patients against a $6,000 investment, a cost per randomized patient of $3,000.
Per-patient site fees in Phase II-III trials typically range from $3,000 to $15,000 per randomized patient. At an estimated $3,000 to $15,000 per-patient site fee, two randomized patients represents a potential $6,000 to $30,000 in patient revenue against a $6,000 campaign investment.
For this site, the more material outcome was protocol adherence: the enrollment window was met, the sponsor relationship was maintained, and the site incurred no financial exposure when the campaign was initiated. The randomization commitment transferred recruitment risk to Clinical Enroll before a dollar was spent.
POTENTIAL ROI
$6,000
Campaign investment
$3k-$15k
Per-patient site fee range
$6k-$30k
Potential patient revenue
How Feasibility Was Verified Before Launch
Clinical Enroll evaluated the tezepelumab COPD protocol for feasibility before extending a randomization commitment. With only two randomization slots needed, the review focused on whether the site's catchment area could support the study's narrow exacerbation-history and smoking-status eligibility within the fixed protocol window, at a campaign envelope of $6,000.
- Protocol and eligibility review — study criteria verified against the registered protocol, NCT06883305.
- Addressable population modeling — COPD patient density and exacerbation-history prevalence assessed within the site's catchment area.
- IRB-ready campaign build — condition-targeted creative and channels developed for compliance review.
- Pre-screening — every referral is screened against the study's inclusion and exclusion criteria before reaching the site.
- Contracted randomization commitment — the enrollment target is fixed in writing before the campaign launches.
Read more about how Clinical Enroll runs feasibility assessments before every engagement.
Common questions about this engagement.
See if our guaranteed approach is the right fit for your study.
Book a free consultation to walk through your protocol and enrollment goals. We will tell you whether our guaranteed recruitment model fits your study before you commit anything.
All campaigns developed for IRB review and deployed in accordance with FDA guidance on clinical trial advertising.